OCGN Ocugen Inc
Company Analysis
Latest News
🔴 Ocugen falls 5.1% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...
🟢 Ocugen is trading 10.45% up today after positive Moderna-Merck Phase 3 cancer-vaccine results
Ocugen is trading +10.45% at $1.48 after biotechnology shares rallied broadly on positive Moderna-Merck Phase 3 cancer-vaccine results. - Reuters reported the...
🟢 Ocugen rises 7.1% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
Ocugen targets 2027 gene therapy filings, securing funding through 2028
Ocugen Inc. plans to submit Biologics License Applications for two lead gene therapy candidates in 2027. The company is developing OCU400 for retinitis...
Hennion & Walsh doubles Ocugen stake, following FDA Phase 3 clearance
Hennion & Walsh Asset Management Inc. increased its Ocugen, Inc. holdings during the second quarter. The firm boosted its position by 121.7%. It purchased over...
🔴 Ocugen is trading 5% down today after wider loss and $130 million convertible-note financing
Ocugen is trading 5% down now at $1.22 after its August 6, 2026 earnings release showed $1.5 million in revenue but a wider $0.07-per-share loss, while...
Ocugen Inc Q2 2026 Earnings Preview: What Analysts Expect on August 06, 2026
Analysts expect Ocugen to report Q2 2026 revenue of approximately $0.98 million and a loss per share of $0.05, while the current stock price of $1.27 remains...
🟢 Ocugen is trading 5.2% up today amid a broader biotech sector rally
Ocugen is trading 5.2% up at $1.31 today, moving in tandem with a broader biotech sector rally rather than company-specific news. • The move aligns with the...
🟢 Ocugen is trading 5.5% up today amid a broader market rally
Ocugen is trading 5.5% up at $1.25 today, rebounding after yesterday’s profit-taking drop and sector-wide weakness. • The move appears driven by renewed...
🔴 Ocugen is trading 5.2% down today on profit-taking and broader biotech sector weakness
Ocugen is trading at $1.18 (5.2% down) today as investors take profits following a recent rally sparked by FDA RMAT designation for its OCU410 gene therapy. •...
Ocugen Wins FDA RMAT Status for Blindness Gene Therapy, Accelerating Review
Ocugen received U.S. Food and Drug Administration (FDA) Regenerative Medicine Advanced Therapy (RMAT) designation for its gene therapy candidate, OCU410. The...
🟢 Ocugen rises 5.8% — Biotech Sector Rallies on Blockbuster M&A Deal and Positive Trial Data
With Biotech (XBI) up 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector is experiencing a significant...
Ocugen Proposes 250 Million Share Increase to Fuel BLA Pipeline
Ocugen, Inc. scheduled a special virtual stockholder meeting for September 21, 2026. The board of directors unanimously recommended increasing authorized...
🔴 Ocugen is trading 5.3% down today on normal volatility despite a rising biotech sector
Ocugen is trading 5.3% down at $1.26 today on normal volatility, as there are no fresh company-specific headlines or trial updates to drive the move. • The...
🔴 Ocugen is trading 5.2% down today amid a weak biotech tape and broader risk-off sentiment
Ocugen is trading 5.2% down now at $1.35 amid a weak biotech tape and broader risk-off sentiment. • Shares are likely drifting lower following prior...
Ocugen Targets 2025 Filings for Eye Gene Therapies, Reporting Zero Safety Issues
Ocugen Inc. presented a gene therapy pipeline update at the Piper Sandler Virtual Ophthalmology Day on July 10, 2026. The company's strategy focuses on...
Ocugen signs OCU400 licensing term sheet for MENA region worth up to $259M
Ocugen, Inc. announced it has signed a binding term sheet with Roots Pharmaceutical to license and commercialize OCU400, its gene therapy for Retinitis...
🔴 Ocugen is trading 5.3% down today amid convertible notes deal volatility and Q1 losses
Ocugen is trading at $1.42 (5.3% down) amid continued volatility following its $115 million convertible notes deal and wider Q1 losses, which previously...
🟢 OCGN is trading 6% up today after analyst support held despite a lower price target
OCGN is trading at 6% up now at $1.56 after Canaccord kept its Buy rating while trimming its price target from $12 to $11.[1] Investor sentiment also stayed...
🔴 OCGN is trading 4.19% down today in a technical pullback after a sharp prior-session rally
OCGN is trading at $1.60 (4.19% down) as the stock undergoes a technical pullback following an 11.33% rally in the previous session. • The move follows a...